ArticleNature medicine2017
Asprosin is a centrally acting orexigenic hormone.
Article in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
179 citing papers in PubMed, 4 syntheses or guidelines pooled it, 336 citations in OpenAlex.
- Systematic review and meta-analysis of the effect of exercise training on asprosin in randomized controlled trials.Physiological reports · 2025Pooled it
- Relationship of asprosin and diabetes: a meta-analysis.BMC endocrine disorders · 2025Pooled it
- Circulating levels of asprosin in children with obesity: a systematic review and meta-analysis.BMC endocrine disorders · 2024Pooled it
- Pooled it
- Spirulina supplementation and circuit resistance training (CRT) reduce serum asprosin and appetite and improve energy balance in men with obesity and overweight.Hormones (Athens, Greece) · 2025Trial
- Effects of exercise and dietary interventions on asprosin, leptin, and lipid metabolism in males with abdominal obesity, a randomized controlled trial.Scientific reports · 2024Trial
- Exercise-induced effects on asprosin and indices of atherogenicity and insulin resistance in males with metabolic syndrome: a randomized controlled trial.Scientific reports · 2024Trial
- CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study.International journal of obesity (2005) · 2022Trial
- The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients.Scientific reports · 2019Trial
- Curcumin modulates the adipose FBN1-Asprosin axis and improves metabolic dysfunction in a rat model of type 2 diabetes.Metabolism open · 2026Article
- Asprosin-driven metabolic-epigenetic rewiring attenuates mesenchymal stem cell senescence with therapeutic benefits for infarcted hearts.Journal of advanced research · 2026Article
- Adipose tissue as a humoral-neuronal hub in metabolic regulation.Nature reviews. Endocrinology · 2026Review
- Observational
- Gingival crevicular fluid asprosin, adropin, and irisin hormone levels in the different periodontal status.Clinical oral investigations · 2026Article
- Aortic asprosin overexpression does not ameliorate disease pathophysiology in a murine model of Marfan syndrome.Scientific reports · 2026Article
- Asprosin-PTPRD endocrine resistance links brain dysfunction and systemic wasting in Alzheimer's disease.Research square · 2026Article
- Endocrine regulation of the hepatic fasting response: cues, cooperation and consequences.Nature reviews. Endocrinology · 2026Review
- Circulating Asprosin Concentrations and Body Weight Changes in Postmenopausal Women: Findings from the Women's Health Initiative.The Journal of nutrition · 2026Article
- Expression of asprosin and OLFR734 in reproductive tissues of polycystic ovary syndrome mice: insights into metabolic and reproductive dysfunction.Cell and tissue research · 2026Article
- YY1/Asprosin/PFKP axis regulates glycolytic metabolic and exacerbates pathological cardiac hypertrophy.Nature communications · 2026Article
119 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Funding
Abstract
Asprosin is a recently discovered fasting-induced hormone that promotes hepatic glucose production. Here we demonstrate that asprosin in the circulation crosses the blood-brain barrier and directly activates orexigenic AgRP
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.